SP-0398: Active surveillance for cardiovascular disease after Hodgkins lymphoma  by Daniels, L.
S186                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
regimens in 23 studies.2 Applying these doses to estimated 
typical absolute cardiac risks1 showed the absolute risk of a 
radiation-induced major coronary event for many women 
today is less than 1%. So for them, the risk of radiotherapy is 
likely to be much smaller than the benefit. Nevertheless 
there is considerable variation in predicted absolute cardiac 
risks, depending on an individual woman’s background risk 
and on her heart radiation dose.  
 
Conclusions: Exposure of the heart from breast cancer 
radiotherapy has reduced substantially over the past few 
decades but there is still considerable variation in published 
heart doses worldwide. In addition, there is variation in the 
risk of heart disease among patients being considered for 
radiotherapy. Thus there is likely to be substantial 
interpatient variability in the cardiac risks of radiotherapy. 
The population-based dose-response relationship1 can be 
used to provide reassurance for many women that their 
absolute risk of ischaemic heart disease from breast cancer 
radiotherapy is likely to be small compared with their likely 
absolute benefit. For other women, for example those with a 
high predicted heart radiation dose or for those with prior 
heart disease, the dose-response relationship can be used to 
identify the minority of women for whom the risk-benefit 
ratio is less favourable. In these women, consideration may 
be given to reducing cardiac radiation dose to reduce the 
radiation-related cardiac risk.  
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The QUANTEC summary of data on dose-volume-response 
effect in heart after radiation therapy provided some answers 
and practical guidelines for the optimization of the dose 
distribution in breast cancer patients, and left a few 
problems open. The main dilemma centered on the fact that 
cardiac serious events are late, requiring long follow-up and 
rare, requiring large populations. Furthermore, in studies 
evaluating cardiac toxicities after irradiation the quality of 
the outcome clinical data was in general different from the 
quality of the dosimetrical data. Similar considerations still 
apply to a few studies performed after QUANTEC.  
A main step forward is represented by the increased size and 
design of the studies, e.g. as in the one by Darby et al (N 
Engl J Med 2013) which included about 2.000 women treated 
in Scandinavia. The paper provided among several results an 
estimation of the cumulative risk of death from ischemic 
heart disease for patients treated/not treated with radiation 
therapy and with different mean heart doses, obtained 
through reconstruction of the dose planning on a model 
patient.  
Beyond size and type of study population another relevant 
factor investigated in several analysis is the relationship 
between fraction size and late cardiac effects. Mahrin ( Int J 
Radiation Oncology Biol. Phys. 2007) performed an analysis 
on about 3.800 left sided respectively 3700 right sided breast 
cancer patients treated between 1984 and 2000, compared 
the different fractionation schedules and concluded that a 
statistical increase in overall and cardiac-specific mortality 
could not be found comparing left vs right breast cancer 
patients. Furthermore the hypofractionated adjuvant RT 
regimens did not significantly increase the risk of cardiac 
mortality. The 10 year follow-up of the START - UK 
Standardization of Breast Cancer Radiotherapy trials of 
radiotherapy hypofractionation (Haviland JS et al, Lancet 
Oncol 2013) confirmed the 5 years results that “appropriately 
dosed hypofractionated radiotherapy is safe and effective”. A 
norwegian study with a longer follow-up, but a smaller study 
population and irradiated in a different way concluded 
instead than the degree of hypofractionation and parasternal 
nodes contributed to an increased cardiac mortality in the 
patient cohort (Tjessem et al, Int J Radiation Oncology Biol. 
Phys 2013).  
Another perspective is given by the studies on cardiac dose-
volume effects where dose distributions in subregions of the 
heart are investigated (e.g. Nilsson G et al, J Clin Oncol 
2012; Johansen S, Breast cancer: basic and clinical research 
2013). The results from these analyis might be very helpful in 
the design of treatment protocols.  
Finally the technological development has to be taken into 
account (e.g. gating, DIBH etc), which in some cases might 
simply by-pass the issue of cardiac irradiation. This approach 
does not provide answers to the basic question, but provides 
a convenient solution.  
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Hodgkin lymphoma is a relatively rare form of cancer, which 
mainly effects young adolescents and young adults. Over the 
past decades developments in treatment options for patients 
with Hodgkin lymphoma have led to improved outcome rates. 
As a result, there is an increasing number of Hodgkin 
lymphoma survivors. They are at risk of developing long-term 
toxicity due to treatment such as secondary malignancies or 
cardiovascular complications. There is an increased risk of 
developing valvular heart disease after mediastinal 
radiotherapy, although risk increases significantly after 
radiation treatment doses over 30 Gy (1). Recent studies also 
show a 4-6 fold increased standardized incidence ratio of 
heart failure and coronary heart disease (CHD), due to 
anthracycline containing chemotherapy regimens and 
mediastinal radiotherapy (2). Severe CHD can even be 
present in the absence of typical symptoms such as chest 
pain (3). A linear dose-response relationship between 
mediastinal radiotherapy and CHD has been established with 
a 2.5-fold increased risk of CHD after receiving a mean heart 
dose of 20 Gy (4). This implies that even patients treated 
with current standard radiotherapy doses remain at serious 
risk of developing radiation induced CHD. At the same time, 
new strategies for non-invasive screening for CHD have 
developed, by means of CT coronary angiography, showing 
encouraging positive and negative predictive values for 
detecting significant CHD. In this lecture, an overview of 
recent efforts of screening for coronary artery disease in 
Hodgkin lymphoma patients is presented, and clinical 
implications are discussed. 
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